Literature DB >> 28038941

Design and synthesis of new coumarin hybrids and insight into their mode of antiproliferative action.

Heba A H Elshemy1, Mohamed A Zaki2.   

Abstract

Molecular hybridization approach was used to synthesize three series of coumarin based hybrids by conglomerate a substituted chalcones, acrylohydrazides, and pyridines moieties with 8-methoxy coumarin. The hybrids showed significant cytotoxic activity against liver cancer Hep G2 and Leukemia K562 cell lines with IC50 values 0.49-3.96μM, comparable to the positive controls and exhibited weak activity against the normal cell line WI-38, thus indicating selectivity toward the tumor cells. Coumarin-chalcone hybrids 2a-c have demonstrated the most promising activity against both cancer cell lines with IC50 values of 0.65-2.02μM. Interestingly, the acrylohydrazide hybrid 4c showed the highest cytotoxic activity against the leukemia cell line (K562) with IC50 value of 0.49μM. All the investigated coumarin hybrids were able to increase the caspase-3 and caspase-9 proteins level expression relative to that of the untreated cells suggesting that coumarin hybrids-induced apoptosis was, in part, due to activation of caspases 3 and 9. Apoptosis was further confirmed with down-regulation of Bcl-2 and up-regulation of Bax protein expression level. Furthermore, cell cycle analysis of 2a and 4c showed apoptotic signals activation, as a consequence of arrest in G2/M phase. Results of our study can shed light on coumarin-based hybrids as promising anticancer leads.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acrylohydrazide; Antiproliferative; Apoptosis; BAX; Bcl-2; Caspase; Chalcones; Coumarins; Molecular hybridization

Mesh:

Substances:

Year:  2016        PMID: 28038941     DOI: 10.1016/j.bmc.2016.12.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

Review 1.  Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids.

Authors:  Harbinder Singh; Jatinder Vir Singh; Kavita Bhagat; Harmandeep Kaur Gulati; Mohit Sanduja; Nitish Kumar; Nihar Kinarivala; Sahil Sharma
Journal:  Bioorg Med Chem       Date:  2019-06-22       Impact factor: 3.641

2.  Synthesis and Antiproliferative Activity of Novel Dehydroabietic Acid-Chalcone Hybrids.

Authors:  Sophia Grigoropoulou; Dimitra Manou; Antonia I Antoniou; Artemis Tsirogianni; Carlo Siciliano; Achilleas D Theocharis; Constantinos M Athanassopoulos
Journal:  Molecules       Date:  2022-06-05       Impact factor: 4.927

3.  Design, Synthesis and Molecular Docking Analysis of Flavonoid Derivatives as Potential Telomerase Inhibitors.

Authors:  Zhan-Fang Fan; Sai-Tim Ho; Rui Wen; Ya Fu; Lei Zhang; Jian Wang; Chun Hu; Pang-Chui Shaw; Yang Liu; Mao-Sheng Cheng
Journal:  Molecules       Date:  2019-09-01       Impact factor: 4.411

Review 4.  A Review on Anti-Tumor Mechanisms of Coumarins.

Authors:  Yi Wu; Jing Xu; Yiting Liu; Yiyu Zeng; Guojun Wu
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

5.  Coumarin Sulfonamides and Amides Derivatives: Design, Synthesis, and Antitumor Activity In Vitro.

Authors:  Jing Zhang; Yaling Tan; Guorong Li; Lexian Chen; Minyi Nie; Zhaohua Wang; Hong Ji
Journal:  Molecules       Date:  2021-02-03       Impact factor: 4.411

6.  Synthesis, docking studies, biological activity of carbon monoxide release molecules based on coumarin derivatives.

Authors:  Huapeng Liu; Yujie Chen; Fujun Cui; Yuan Liao; Xicun Wang
Journal:  Front Chem       Date:  2022-09-29       Impact factor: 5.545

7.  Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.

Authors:  Saman Khan; Ali Mohammed Malla; Atif Zafar; Imrana Naseem
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

8.  A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Authors:  Patricia Martín-Rodríguez; Borja Guerra; Idaira Hueso-Falcón; Haidee Aranda-Tavío; Juan Díaz-Chico; José Quintana; Francisco Estévez; Bonifacio Díaz-Chico; Angel Amesty; Ana Estévez-Braun; Leandro Fernández-Pérez
Journal:  Front Pharmacol       Date:  2019-01-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.